Sicong Lai1,2, Xiaoying Lou3, Xinjuan Fan3, Weipeng Sun4, Yanhong Deng5, Jianping Wang2, Yan Huang3, Ruoxu Dou1. 1. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. 2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. 3. Department of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. 4. Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China. 5. Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Abstract
BACKGROUND: Lymphocytic density in rectal cancer has been reported to be associated with therapeutic response, but the role of the lymphocytic distribution pattern remains to be determined. This study aimed to evaluate the association between the distribution and density of lymphocytes in rectal-cancer tissue with tumor response to neoadjuvant therapy. METHODS: We retrospectively analysed 134 patients with rectal cancer receiving neoadjuvant therapy within a prospectively maintained cohort. Pretherapeutic biopsy samples were stained with immunohistochemistry (CD4 and CD8). Densities of intratumoral periglandular lymphocytes (IPLs) and tumor-infiltrating lymphocytes (TILs) were assessed separately. Logistic-regression analysis was used to assess associations of lymphocyte densities with tumor regression grade (TRG), controlling for clinicopathological, molecular, and regimen features. RESULTS: Compared with cases in the lowest quartile of CD8+ TILs, those in the highest quartile were significantly associated with better TRG (multivariate odds ratio, 0.23; 95% confidence interval, 0.07 to 0.76; P < 0.001). In contrast, CD8+ IPLs, CD4+ IPLs, and CD4+ TILs were not significantly associated with TRG (P = 0.033, 0.156, and 0.170, respectively). Sensitivity analyses detected no interaction between CD8+ TILs and regimen of neoadjuvant radiation (P interaction = 0.831) or chemotherapy (P interaction = 0.879) on TRG. CONCLUSIONS: Our data suggest that CD8+ TILs, but not IPLs, are independently associated with response to neoadjuvant therapy, regardless of the regimen of radiation or chemotherapy.
BACKGROUND: Lymphocytic density in rectal cancer has been reported to be associated with therapeutic response, but the role of the lymphocytic distribution pattern remains to be determined. This study aimed to evaluate the association between the distribution and density of lymphocytes in rectal-cancer tissue with tumor response to neoadjuvant therapy. METHODS: We retrospectively analysed 134 patients with rectal cancer receiving neoadjuvant therapy within a prospectively maintained cohort. Pretherapeutic biopsy samples were stained with immunohistochemistry (CD4 and CD8). Densities of intratumoral periglandular lymphocytes (IPLs) and tumor-infiltrating lymphocytes (TILs) were assessed separately. Logistic-regression analysis was used to assess associations of lymphocyte densities with tumor regression grade (TRG), controlling for clinicopathological, molecular, and regimen features. RESULTS: Compared with cases in the lowest quartile of CD8+ TILs, those in the highest quartile were significantly associated with better TRG (multivariate odds ratio, 0.23; 95% confidence interval, 0.07 to 0.76; P < 0.001). In contrast, CD8+ IPLs, CD4+ IPLs, and CD4+ TILs were not significantly associated with TRG (P = 0.033, 0.156, and 0.170, respectively). Sensitivity analyses detected no interaction between CD8+ TILs and regimen of neoadjuvant radiation (P interaction = 0.831) or chemotherapy (P interaction = 0.879) on TRG. CONCLUSIONS: Our data suggest that CD8+ TILs, but not IPLs, are independently associated with response to neoadjuvant therapy, regardless of the regimen of radiation or chemotherapy.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl Journal: Lancet Oncol Date: 2017-12-07 Impact factor: 41.316
Authors: In Ja Park; Y Nancy You; Atin Agarwal; John M Skibber; Miguel A Rodriguez-Bigas; Cathy Eng; Barry W Feig; Prajnan Das; Sunil Krishnan; Christopher H Crane; Chung-Yuan Hu; George J Chang Journal: J Clin Oncol Date: 2012-04-09 Impact factor: 44.544
Authors: A Buckowitz; H-P Knaebel; A Benner; H Bläker; J Gebert; P Kienle; M von Knebel Doeberitz; M Kloor Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Jérôme Galon; Bernhard Mlecnik; Gabriela Bindea; Helen K Angell; Anne Berger; Christine Lagorce; Alessandro Lugli; Inti Zlobec; Arndt Hartmann; Carlo Bifulco; Iris D Nagtegaal; Richard Palmqvist; Giuseppe V Masucci; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Michele Maio; Luigi Laghi; Fabio Grizzi; Martin Asslaber; Corrado D'Arrigo; Fernando Vidal-Vanaclocha; Eva Zavadova; Lotfi Chouchane; Pamela S Ohashi; Sara Hafezi-Bakhtiari; Bradly G Wouters; Michael Roehrl; Linh Nguyen; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Yili Wang; Scott Kopetz; Frank A Sinicrope; Viorel Scripcariu; Paolo A Ascierto; Francesco M Marincola; Bernard A Fox; Franck Pagès Journal: J Pathol Date: 2014-01 Impact factor: 7.996
Authors: Livius Penter; Kerstin Dietze; Julia Ritter; Maria Fernanda Lammoglia Cobo; Josefin Garmshausen; Felix Aigner; Lars Bullinger; Holger Hackstein; Sandra Wienzek-Lischka; Thomas Blankenstein; Michael Hummel; Klaus Dornmair; Leo Hansmann Journal: Oncoimmunology Date: 2019-03-24 Impact factor: 8.110
Authors: David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar Journal: Lancet Date: 2009-03-07 Impact factor: 79.321